Skip to main content
A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy. Read More ›

Differences in tumor immune microenvironment, including immune cells infiltrated in tumors and PD-L1 expression, show links to the divergent response to immune checkpoint inhibitors in patients with KRAS mutation and STK11 co-mutation. Read More ›

Despite apparent therapeutic efficacy and guideline recommendations, predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with NSCLC have not been widely implemented in the community oncology setting. Read More ›

According to the findings of a new trial, an investigational therapy for a second-line NSCLC treatment was found to be well-tolerated and active against KRAS mutations. Read More ›

The development of targeted therapies in cancer treatment is a key factor in improving patient care. Overcoming many current challenges will be crucial in improving access to precision medicine. Read More ›

Mental burden is the number 1 impact on patients with lung cancer QOL, followed by the physical effects of their disease and treatment, whereas caregivers are more concerned with their patients’ QOL than their patients’ lung cancer stage. Read More ›

Patients receiving chronic ICI therapy with any chronic lung disease, including NSCLC, should undergo pre- and posttreatment testing to ensure timely interventions for any signs of pneumonitis. Corticosteroid therapy or ICI withdrawal should be initiated immediately to aid in prompt patient recovery. Read More ›

Most cannabis smokers with advanced NSCLC do not have any detectable genetic drivers and their use of marijuana appears to aid their NSCLC tumor growth. Read More ›

KRAS mutation testing remains limited, although it is growing. Sotorasib is the first KRAS inhibitor to be FDA approved for KRAS mutation–positive, metastatic NSCLC, making it more important than ever before for physicians to consider testing for KRAS mutations. Read More ›

Patients with NSCLC and KRAS mutation treated with ICI monotherapy show longer OS and longer PFS when compared with patients with non-KRAS NSCLC. Read More ›

Page 2 of 16